InterMune

InterMune

InterMune was a biotechnology company based in Brisbane, California focused on developing therapies for pulmonary fibrosis, cystic fibrosis, and rare infectious disease indications. The company conducted clinical development, regulatory interactions with agencies such as the Food and Drug Administration and the European Medicines Agency, and commercial activities in markets including the United States, European Union, and Japan. InterMune engaged with academic centers, biotechnology firms, and pharmaceutical companies to advance antifibrotic and immunomodulatory medicines.

History

InterMune was founded in 1990 in California and emerged during a period of rapid expansion in the biotech industry alongside contemporaries such as Genentech, Amgen, and Biogen. Early leadership included executives who had roles at companies like Chiron Corporation and Gilead Sciences. Throughout the 1990s and 2000s, the company pursued development programs in infectious disease and pulmonology, collaborating with academic investigators at institutions including Stanford University, University of California, San Francisco, and Johns Hopkins University. InterMune's corporate strategy involved licensing agreements, research collaborations, and pursuing regulatory approvals across jurisdictions including the United States, European Union, and Japan. In 2014, InterMune was acquired by F. Hoffmann-La Roche (Roche), a multinational headquartered in Basel, marking consolidation among large pharmaceutical companies such as Pfizer, GlaxoSmithKline, and Novartis.

Products and Research

InterMune's pipeline centered on antifibrotic compounds and immunotherapies. Its lead commercial product was a small-molecule antifibrotic treatment developed for idiopathic pulmonary fibrosis (IPF), a progressive interstitial lung disease studied at centers including Mayo Clinic and Mount Sinai Health System. The company also developed programs in cystic fibrosis with connections to research at University of North Carolina at Chapel Hill and collaborations with patient organizations such as the Cystic Fibrosis Foundation. Earlier-stage work included recombinant biologics and repurposed agents in partnership with biotechnology firms like Genzyme and academic labs at Harvard Medical School and Massachusetts General Hospital. InterMune engaged clinical investigators from sites including Cleveland Clinic, University of Pittsburgh Medical Center, and Brigham and Women's Hospital for trial conduct and mechanistic studies.

Clinical Trials and Approvals

InterMune conducted multiple randomized, placebo-controlled clinical trials, registrational programs, and postmarketing studies across respiratory and orphan-disease indications. The company submitted dossiers to regulatory bodies such as the Food and Drug Administration and the European Medicines Agency, navigating advisory committee reviews similar to those faced by companies like AstraZeneca and Eli Lilly. InterMune’s pivotal trials included phase II and phase III studies enrolling patients at tertiary centers including Johns Hopkins Hospital and Royal Brompton Hospital. Outcomes assessed pulmonary function endpoints, exacerbation rates, and mortality, with safety monitoring comparable to trials run by GlaxoSmithKline and Roche. Regulatory interactions involved national agencies including the Ministry of Health, Labour and Welfare (Japan) for Japanese approvals and the Medicines and Healthcare products Regulatory Agency for the United Kingdom market.

Partnerships and Acquisitions

Throughout its corporate lifecycle, InterMune entered licensing, collaboration, and co-development agreements with multinational companies and specialized biotech firms. These included deals resembling partnerships between Amgen and academic spinouts, or licensing arrangements like those between Roche and smaller biotech companies. InterMune collaborated with contract research organizations and manufacturing partners based in the United States, Europe, and Asia to scale clinical production. The company's acquisition by Roche in 2014 integrated its assets into a global portfolio alongside products from Genentech and other Roche affiliates, reflecting broader consolidation trends also seen in transactions involving Sanofi and Bristol-Myers Squibb.

Controversies and Legal Issues

InterMune's development and commercial activities encountered regulatory scrutiny, safety debates, and litigation common in the pharmaceutical industry. Postmarketing safety data and label negotiations with bodies such as the Food and Drug Administration prompted discussion among academic researchers at Yale School of Medicine and Columbia University Vagelos College of Physicians and Surgeons. Patent disputes and intellectual property litigation paralleled cases involving companies like Merck and Bayer, with matters adjudicated in courts that handle pharmaceutical IP. Shareholder actions and securities litigation arose around regulatory decisions and acquisition terms similar to precedents involving Valeant Pharmaceuticals and Allergan. Additionally, pricing and access discussions engaged health technology assessment bodies such as the National Institute for Health and Care Excellence and payer organizations in Germany and France.

Category:Biotechnology companies of the United States Category:Pharmaceutical companies established in 1990 Category:2014 mergers and acquisitions